Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 163
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03888365 | Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH | ||
| NCT01353040 | Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus | ||
| NCT00651885 | Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure | ||
| NCT04870333 | PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V | ||
| NCT01260454 | The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain | ||
| NCT01588405 | Remodulin® to Oral Treprostinil Transition | ||
| NCT02847260 | Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) | ||
| NCT02360345 | Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly | ||
| NCT02893995 | Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension | ||
| NCT00439946 | Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH | ||
| NCT00508586 | PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | ||
| NCT04411680 | Study of Sargramostim in Patients With COVID-19 | ||
| NCT03045029 | ADAPT - A Patient Registry of the Real-world Use of Orenitram® | ||
| NCT01007890 | Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer | ||
| NCT00373360 | Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin | ||
| NCT01557660 | Inhaled Treprostinil for PAH: Open-label Extension | ||
| NCT01884038 | Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients | ||
| NCT05255991 | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | ||
| NCT02261883 | Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn | ||
| NCT05564637 | A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension | ||
| NCT01268553 | Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication | ||
| NCT00458042 | Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction | ||
| NCT06477640 | Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension | ||
| NCT02149095 | Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers | ||
| NCT03055234 | Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) | ||
| NCT00760916 | FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) | ||
| NCT06580444 | Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study | ||
| NCT01934582 | A Pharmacokinetic Substudy of the TDE-PH-304 Protocol | ||
| NCT02370095 | Treprostinil Sodium Inhalation for Patients At High Risk for ARDS | ||
| NCT04090866 | Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study | ||
| NCT00325442 | FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) | ||
| NCT03367312 | Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI | ||
| NCT01447407 | Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine | ||
| NCT00963001 | Effect of Food on the Pharmacokinetics of Oral Treprostinil | ||
| NCT04865393 | Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function | ||
| NCT03180957 | Repurposing Anti-TNF for Treating Dupuytren's Disease | ||
| NCT01302444 | Treprostinil Combined With Tadalafil for Pulmonary Hypertension | ||
| NCT00692354 | Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours | ||
| NCT03037580 | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction | ||
| NCT00775463 | Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine | ||
| NCT07116681 | Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | ||
| NCT01266265 | Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies | ||
| NCT03683186 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | ||
| NCT06911632 | Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension | ||
| NCT01592045 | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma | ||
| NCT06450041 | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | ||
| NCT00067041 | Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft | ||
| NCT03481725 | Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Department of Defense Funded Multicenter Pilot Study | ||
| NCT00848939 | Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis | ||
| NCT03043651 | Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF |
